Polyrizon Ltd. (NASDAQ:PLRZ) Short Interest Update

Polyrizon Ltd. (NASDAQ:PLRZ) was the target of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 51,385 shares, a decrease of 57.2% from the January 15th total of 120,032 shares. Currently, 4.9% of the company’s stock are short sold. Based on an average trading volume of 71,761 shares, the short-interest ratio is currently 0.7 days. Based on an average trading volume of 71,761 shares, the short-interest ratio is currently 0.7 days. Currently, 4.9% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Polyrizon in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Polyrizon Stock Down 1.0%

Shares of NASDAQ:PLRZ opened at $13.85 on Friday. The stock’s 50-day moving average is $12.34 and its 200-day moving average is $8.38. Polyrizon has a 52-week low of $2.88 and a 52-week high of $2,235.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC purchased a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon as of its most recent SEC filing.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.